Hematology (all articles)
Brief Review: Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery.
6 Jun, 2022 | 10:55h | UTC
BSH Guidelines for thrombophilia testing.
2 Jun, 2022 | 11:28h | UTCGuidelines for thrombophilia testing: A British Society for Haematology guideline
NIH Updated Guideline: Antithrombotic therapy in patients with COVID-19.
2 Jun, 2022 | 11:25h | UTCAntithrombotic Therapy in Patients With COVID-19 – National Institutes of Health
Cohort Study: Risk of hematologic cancer in patients with undifferentiated pruritus.
30 May, 2022 | 10:35h | UTCRisk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live
Cohort Study: Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
27 May, 2022 | 11:56h | UTCEditorial: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities
Commentary on Twitter
The natural history of Transthyretin Amyloid Cardiomyopathy (ATTR-CM): disease course and clinical outcome among patients diagnosed with early-stage of disease!#amyloid #heart #failure #cardiac #amyloidosis@escardio @ESC_Journals
https://t.co/uvydC3gisD pic.twitter.com/ooKyjeGVNe
— EHJ Editor-in-Chief (@ehj_ed) May 25, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
26 May, 2022 | 10:57h | UTCRelated:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Second Revision of the International Staging System (R2-ISS) for overall survival in Multiple Myeloma.
26 May, 2022 | 10:34h | UTC
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
BIOIRON Society recommends new classification of hemochromatosis.
24 May, 2022 | 08:09h | UTCNews Release: BIOIRON Society Recommends New Classification of Hemochromatosis – ASH Clinical News
See Guidance: Hemochromatosis classification: update and recommendations by the BIOIRON Society – Blood
Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile.
23 May, 2022 | 00:41h | UTC
Commentary on Twitter
A transcriptomic primary plasma cell leukaemia classifier comprising 53 genes had a sensitivity of 93% in pts with newly-diagnosed MM. Multivariate analysis confirmed the prognostic performance of this classifier vs the International Staging System: https://t.co/bD45PQG9bl #MMSM
— NatureRevClinOncol (@NatRevClinOncol) April 7, 2022
RCT: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma.
19 May, 2022 | 10:39h | UTCAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser
Commentary on Twitter
NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN
— The Lancet Haematology (@TheLancetHaem) May 12, 2022
Review: Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis.
18 May, 2022 | 10:46h | UTC
Commentary on Twitter
Our work on this review summarises the pharmacological profile of DOACs and highlights the use of #DOACs in post-operative #VTE prophylaxis based on the available clinical trialhttps://t.co/7MRvWBfaEG @radcliffeCARDIO @mmamas1973 @AnastasiaSMihai @mirvatalasnag @KardiologieHH pic.twitter.com/MW6n2CWGe0
— Henry Han (@HanCardiomd) May 13, 2022
Under a CC-BY-NC 4.0 license
How I Treat series on plasma cell dyscrasias.
18 May, 2022 | 10:31h | UTCEditorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood
How I treat relapsed multiple myeloma – Blood
How I treat frontline transplantation-eligible multiple myeloma – Blood
Guideline Synopsis: Antithrombotic therapy for venous thromboembolism.
17 May, 2022 | 11:12h | UTCAntithrombotic Therapy for Venous Thromboembolism – JAMA (free for a limited period)
Original Guideline: Antithrombotic Therapy for VTE Disease
Second Update of the CHEST Guideline and Expert Panel Report
Cohort Study: Venous or arterial thrombosis and deaths among COVID-19 cases.
17 May, 2022 | 11:02h | UTCInvited Commentary: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases
News Release: COVID-19’s high blood clot risk – University of Oxford
Commentary on Twitter
Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm
— Eric Topol (@EricTopol) May 13, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
Cohort Study: Sustainability of a clinical decision support intervention for outpatient care for emergency department patients with acute pulmonary embolism.
17 May, 2022 | 10:44h | UTCRelated: Outpatient versus inpatient treatment for acute pulmonary embolism – Cochrane Library
Commentary on Twitter
This multicenter cohort study of ED patients with acute pulmonary embolism found the initial increase in outpatient management from a physician champion-led, EHR-embedded clinical decision support intervention was sustained 4 years later. https://t.co/UPf8pAOTry
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022
RCT: Fixed-duration Ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities.
16 May, 2022 | 01:47h | UTC
Commentary on Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022
M-A: Direct oral anticoagulants not as effective as vitamin K antagonists in patients with antiphospholipid syndrome.
13 May, 2022 | 10:43h | UTC
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukemia, by subtype, during 2000–14: analysis of individual data from 258 cancer registries in 61 countries.
12 May, 2022 | 10:02h | UTC
Review: Hemophagocytic Lymphohistiocytosis in patients with HIV.
11 May, 2022 | 10:47h | UTCA Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases
Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?
3 May, 2022 | 11:04h | UTCCOUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST
See also: Rebuttal From Dr Tritschler et al – CHEST
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.
29 Apr, 2022 | 10:51h | UTC
Commentary on Twitter
🆕💥Review Article @ASHE_Journal
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/ToPLQXtC4r pic.twitter.com/pZQWWb3ZSx— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) April 28, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
State of the Art Review: Novel treatments in B cell non-Hodgkin’s lymphomas.
22 Apr, 2022 | 09:24h | UTCNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Commentary on Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
British Guideline for the treatment of chronic lymphocytic leukemia.
21 Apr, 2022 | 10:00h | UTCGuideline for the treatment of chronic lymphocytic leukaemia – British Journal of Haematology